Ofatumumab for Multiple Sclerosis Does Not Increase COVID-19 Severity
Presenting at CMSC 2022, researchers evaluated COVID-19 outcomes among patients with MS who received treatment with ofatumumab.
Multiple Sclerosis
Risk for Multiple Sclerosis Relapse After Ponesimod Therapy Discontinuation
Researchers sought to determine whether patients who discontinued treatment with ponesimod had an increased risk for MS disease activity exacerbation.
Humoral Response to COVID-19 mRNA Vaccine in Patients With MS Receiving DMTs
Presenting at CMSC 2022, researchers evaluated the response to the mRNA-1273 vaccine in patients who received DMTs for MS.
Role of Race, Income in Optic Neuritis in Patients With NMOSD or MOGAD
Presenting at CMSC 2022, researchers evaluated whether racial patterns exist in NMOSD- and MOGAD-associated ON and the potential role of social disadvantage in these patterns.
Assessing Electrocardiography Alterations in Patients With Multiple Sclerosis
Presenting at CMSC 2022, researchers observed how ECG patterns relate to different demographic, clinical, and patient-specific characteristics in patients with MS.
Safety, Efficacy of Cladribine for Relapsing-Remitting MS: Real-World Data
Presenting at CMSC 2022, researchers obtained real-world data on the efficacy and safety of oral cladribine in patients with relapsing-remitting multiple sclerosis.
TMS for Multiple Sclerosis: Can It Help Treat Depressive Symptoms?
In a quantitative study, researchers assessed the efficacy of TMS on depressive symptoms in people with MS.
Neurofilament Light Chain Levels May Predict Multiple Sclerosis Disease Activity
Presenting at CMSC 2022, researchers evaluated the prognostic value of baseline NfL for predicting clinical relapse and change in MRI lesion activity among patients with MS.
Lesion Volume Changes Predict Rate of Whole-Brain Atrophy in Multiple Sclerosis
Presenting at CMSC 2022, researchers analyzed the development of whole-brain atrophy and white matter lesions in patients with CDMS.
Ocrelizumab May Affect Prognostic Value of JCV Antibody Index in Multiple Sclerosis
Presenting at CMSC 2022, researchers evaluated the decline in the anti-JCV antibody index in patients with MS through 2 years of ocrelizumab treatment.
- Loading...
Loading...
Next post in CMSC 2022
Loading... 
Loading...